Recent advances in pathophysiology and biomarkers of sepsis-induced acute kidney injury

Journal of Infection

Volumn 72, Issue 2, 2016, Pages 131-142

  Umbro, Ilaria ^a,b   Gentile, Giuseppe ^b   Tinti, Francesca ^a,b   Muiesan, Paolo ^a   Mitterhofer, Anna Paola ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute kidney injury; Microparticles; Prognostic markers; Sepsis; Sepsis pathophysiology; Sepsis induced acute kidney injury

Indexed keywords

ALPHA 1 MICROGLOBULIN; BINDING PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PRESEPSIN; PROCALCITONIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER;

ACUTE KIDNEY FAILURE; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; DIAGNOSTIC VALUE; HUMAN; INCIDENCE; INFLAMMATION; MEMBRANE MICROPARTICLE; MICROALBUMINURIA; MICROANGIOPATHY; MORTALITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SEPSIS; ACUTE KIDNEY INJURY; ANIMAL; COMPLICATION; DISEASE MODEL;

ACUTE KIDNEY INJURY; ANIMALS; BIOMARKERS; DISEASE MODELS, ANIMAL; HUMANS; SEPSIS;

EID: 84960356521     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2015.11.008     Document Type: Review

References (147)

1. Van der Poll T., Opal S.M. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008, 8:32-43.
2. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference, Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20(6):864-874.
3. Levy M.M., Fink M.P., Marshall J.C., Abraham E., Angus D., Cook D., et al. For the International Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003, 31(4):1250-1256.
4. Nguyen H.B., Smith D. Sepsis in the 21st century: recent definitions and therapeutic advances. Am J Emerg Med 2007, 25:564-571.
5. Bone R.C., Sprung C.L., Sibbald W.J. Definitions for sepsis and organ failure. Crit Care Med 1992, 20:724-726.
6. Dickson S. Sepsis and multiple organ failure. Anaesth Inten Care Med 2009, 10:165-168.
7. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
8. Chertow G.M., Burdick E., Honour M., Bonventre J.V., Bates D.W. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005, 16:3365-3370.
9. Uchino S., Kellum J.A., Bellomo R., Doig G.S., Morimatsu H., Morgera S., et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005, 294:813-818.
10. Schrier R.W., Wang W. Acute renal failure and sepsis. New Engl J Med 2004, 351:159-169.
11. Oppert M., Engel C., Brunkhorst F.-M., Bogatsch H., Reinhart K., Frei U., et al. Acute renal failure in patients with severe sepsis and septic shock- a significant independent risk factor for mortality. Nephrol Dial Transpl 2008, 23:904-909.
12. Bagshaw S.M., Uchino S., Bellomo R., Morimatsu H., Morgera S., Schetz M., et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol 2007, 2:431-439.
13. Tian H., Sun T., Hao D., Wang T., Li Z., Han S., et al. The optimal timing of continuous renal replacement therapy for patients with sepsis-induced acute kidney injury. Int Urol Nephrol 2014, 46:2009-2014. 10.1007/s11255-014-0747-5.
14. Rivers E.P., Ahrens T. Improving outcomes for severe sepsis and septic shock: tools for early identification of at-risk patients and treatment protocol implementation. Crit Care Clin 2008, 24:1-47. 10.1016/j.ccc.2008.04.002.
15. Wan L., Bellomo R., Di G.D., Ronco C. The pathogenesis of septic acute renal failure. Curr Opin Crit Care 2003, 9:496-502.
16. Zarjou A., Agarwal A. Sepsis and acute kidney injury. J Am Soc Nephrol 2011, 22:999-1006. 10.1681/ASN.2010050484.
17. Dellinger R.P., Levy M.M., Rhodes A., Annane D., Gerlach H., Opal S.M., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2012, 2013(41). 580e637. 10.1097/CCM.0b013e31827e83af.
18. Doi K., Yuen P.S., Eisner C., Hu X., Leelahavanichkul A., SchnermannJ J., et al. Reduced production of creatinine limits its use as marker of kidney injury in sepsis. J Am Soc Nephrol 2009, 20:1217-1221. 10.1681/ASN.2008060617.
19. Endre Z.H., Westhuyzen J. Early detection of acute kidney injury: emerging new biomarkers. Nephrology 2008, 13:91-98. 10.1111/j.1440-1797.2007.00905.x.
20. Levy M.M., Fink M.P., Marshall J.C., Abraham E., Angus D., Cook D., et al. 2001 SCCM/EISCM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003, 31:521-524.
21. Cohen J. The immunopathogenesis of sepsis. Nature 2002, 420:885-891.
22. Vincent J.-L., Abraham E. The last 100 years of sepsis. Am J Respir Crit Care Med 2006, 173:256-263.
23. Mackey D., McFall A.J. MAMPs and MIMPs: proposed classifications for inducers of innate immunity. Mol Microbiol 2006, 61:1365-1371.
24. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
25. Meylan E., Tschopp J., Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006, 442:39-44.
26. Fry D.E. Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues. Am Surg 2012, 78(1):1-8.
27. Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J 1991, 5:2567-2574.
28. Foster S.L., Hargreaves D.C., Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007, 447:972-978.
29. Rittirsch D., Flierl M.A., Ward P.A. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008, 8:776-787. 10.1038/nri2402.
30. Amara U., Flierl M.A., Rittirsch D., Klose A., Chen H., Acker B., et al. Molecular intercommunication between the complement and the coagulation systems. J Immunol 2010, 185:5628-5636. 10.4049/jimmunol.0903678.
31. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012, 2:1-138. Kidney Diseases: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012).
32. Angus D.C., van der Poll T. Severe sepsis and septic shock. New Engl J Med 2013, 369:840-851. 10.1056/NEJMra1208623.
33. Nisula S., Kaukonen K.-M., Vaara T., Korhonen A.M., Poukkanen M., Karlsson S., et al. Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study. Intensive Care Med 2013, 39:420-428. The FINNAKI Study Group (2013). 10.1007/s00134-012-2796-5.
34. Bagasha P., Nakwagala F., Kwizera A., Ssekasanvu E., Kalyesubula R. Acute kidney injury among adult patients with sepsis in a low-income country: clinical patterns and short-term outcomes. BMC Nephrol 2015, 16:4. 10.1186/1471-2369-16-4.
35. Hutchins N.A., Unsinger J., Hotchkiss R.S., Ayala A. The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med 2014, 20:224-233. 10.1016/j.molmed.2014.01.002.
36. Bagshaw S.M., George C., Bellomo R. Early acute kidney injury and sepsis: a multicentre evaluation. Crit Care 2008, 12:R47. ANZICS Database Management Committee, Epub 2008 Apr 10. 10.1186/cc6863.
37. Bagshaw S.M., Uchino S., Bellomo R., Morimatsu H., Morgera S., Schetz M., et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol 2007, 2:431-439.
38. Vincent J.L., Sakr Y., Sprung C.L., Ranieri V.M., Reinhart K., Gerlach H., et al. Sepsis occurrence in acutely Ill patients investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34:344-353.
39. Cruz D.N., Bolgan I., Perazella M.A., Bonello M., de Cal M., Corradi V., et al. North East Italian prospective hospital renal outcome survey on acute kidney injury I. North East Italian prospective hospital renal outcome survey on acute kidney injury (NEiPHROS-AKI): targeting the problem with the RIFLE criteria. Clin J Am Soc Nephrol 2007, 2:418-425.
40. Kolhe N.V., Stevens P.E., Crowe A.V., Lipkin G.W., Harrison D.A. Case mix, outcome and activity for patients with severe acute kidney injury during the first 24 hours after admission to an adult, general critical care unit: application of predictive models from a secondary analysis of the ICNARC case mix programme database. Crit Care 2008, 12(1):S2. 10.1186/cc7003.
41. Parrillo J.E. Pathogenetic mechanisms of septic shock. New Engl J Med 1993, 328:1471-1477.
42. Langenberg C., Wan L., Egi M., May C.N., Bellomo R. Renal blood flow in experimental septic acute renal failure. Kidney Int 2006, 69(11):1996-2002.
43. Langenberg C., Bellomo R., May C., Wan L., Egi M., Morgera S. Renal blood flow in sepsis. Crit Care 2005, 9(4):R363-R374.
44. Langenberg C., Bagshaw S.M., May C.N., Bellomo R. The histopathology of septic acute kidney injury: a systematic review. Crit Care 2008, 12:R38. 10.1186/cc6823.
45. Pettilä V., Bellomo R. Understanding acute kidney injury in sepsis. Intensive Care Med 2014, 40(7):1018-1020. 10.1007/s00134-014-3313-9.
46. Lehr H.A., Bittinger F., Kirkpatrick C.J. Microcirculatory dysfunction in sepsis: a pathogenetic basis for therapy?. J Pathol 2000, 190:373-386.
47. Kalakeche R., Hato T., Rhodes G., Dunn K.W., El-Achkar T.M., Plotkin Z., et al. Endotoxin uptake by S1 proximal tubular segment causes oxidative stress in the downstream S2 segment. J Am Soc Nephrol 2011, 22(8):1505-1516. 10.1681/ASN.2011020203.
48. Wu L., Gokden N., Mayeux P.R. Evidence for the role of reactive nitrogen species in polymicrobial sepsis-induced renal peritubular capillary dysfunction and tubular injury. J Am Soc Nephrol 2007, 18(6):1807-1815.
49. Gomez H., Ince C., De Backer D., Pickkers P., Payen D., Hotchkiss J., et al. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock 2014, 41(1):3-11. 10.1097/SHK.0000000000000052.
50. Singh P., Okusa M.D. The role of tubuloglomerular feedback in the pathogenesis of acute kidney injury. Contrib Nephrol 2011, 174:12-21. 10.1159/000329229.
51. Thomson S.C. Adenosine and purinergic mediators of tubuloglomerular feedback. Curr Opin Nephrol Hypertens 2002, 11:81-86.
52. Ishikawa K., Bellomo R., May C.N. The impact of intrarenal nitric oxide synthase inhibition on renal blood flow and function in mild and severe hyperdynamic sepsis. Crit Care Med 2011, 39:770-776. 10.1097/CCM.0b013e318206c1fb.
53. Spronk P.E., Zandstra D.F., Ince C. Bench-to-bedside review: sepsis is a disease of the microcirculation. Crit Care 2004, 8:462-468.
54. De Backer D., Donadello K., Favory R. Link between coagulation abnormalities and microcirculatory dysfunction in critically ill patients. Curr Opin Anaesthesiol 2009, 22:150-154. 10.1097/ACO.0b013e328328d1a1.
55. Sriskandan S., Altmann D.M. The immunology of sepsis. J Pathol 2008, 214:211-223.
56. Ince C., Sinaasappel M. Microcirculatory oxygenation and shunting in sepsis and shock. Crit Care Med 1999, 27:1369-1377.
57. Trzeciak S., Rivers E.P. Clinical manifestations of disordered microcirculatory perfusion in severe sepsis. Crit Care 2005, 9(4):S20-S26.
58. Wan L., Bagshaw S.M., Langenberg C., Saotome T., May C., Bellomo R. Pathophysiology of septic acute kidney injury: what do we really know?. Crit Care Med 2008, 36:S198-S203. 10.1097/CCM.0b013e318168ccd5.
59. Evans R.G., Ince C., Joles J.A., Smith D.W., May C.M., O'Connor P.M., et al. Haemodynamic influences on kidney oxygenation: clinical implications of integrative physiology. Clin Exp Pharmacol Physiol 2013, 40:106-122. 10.1111/1440-1681.12031.
60. Exline M.C., Crouser E.D. Mitochondrial mechanisms of sepsis-induced organ failure. Front Biosci 2008, 13:5030-5041.
61. Lemasters J.J., Nieminen A.L. Mitochondrial oxygen radical formation during reductive and oxidative stress to intact hepatocytes. Biosci Rep 1997, 17:281-291.
62. Biesalski H.K., McGregor G.P. Antioxidant therapy in critical care-is the microcirculation the primary target?. Crit Care Med 2007, 35(9):S577-S583.
63. Cunha F.Q., Assreuy J., Moss D.W., Rees D., Leal L.M., Moncada S., et al. Differential induction of nitric oxide synthase in various organs of the mouse during endotoxaemia: role of TNF-alpha and IL-1-beta. Immunology 1994, 81(2):211-215.
64. Trzeciak S., Cinel I., Dellinger P.R., Shapiro N.I., Arnold R.C., Parrillo J.E., et al. Resuscitating the microcirculation in sepsis: the central role of nitric oxide, emerging concepts for novel therapies, and challenges for clinical trials. Acad Emerg Med 2008, 15(5):399-413. 10.1111/j.1553-2712.2008.00109.x.
65. Holthoff J.H., Wang Z., Seely K.A., Gokden N., Mayeux P.R. Resveratrol improves renal microcirculation, protects the tubular epithelium, and prolongs survival in a mouse model of sepsis-induced acute kidney injury. Kidney Int 2012, 81:370-378. 10.1038/ki.2011.347.
66. Wang Z., Holthoff J.H., Seely K.A., Pathak E., Spencer H.J., Gokden N., et al. Development of oxidative stress in the peritubular capillary microenvironment mediates sepsis-induced renal microcirculatory failure and acute kidney injury. Am J Pathol 2012, 180:505-516. 10.1016/j.ajpath.2011.10.011.
67. Chauhan S.D., Seggara G., Vo P.A., Macallister R.J., Hobbs A.J., Ahluwalia A. Protection against lipopolysaccharide-induced endothelial dysfunction in resistance and conduit vasculature of iNOS knockout mice. FASEB J 2003, 17(6):773-775.
68. Heemskerk S., Masereeuw R., Russel F.G., Pickkers P. Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injury. Nat Rev Nephrol 2009, 5(11):629-640. 10.1038/nrneph.2009.155.
69. Peters K., Unger R.E., Brunner J., Kirkpatrick C.J. Molecular basis of endothelial dysfunction in sepsis. Cardiovasc Res 2003, 60:49-57.
70. Mesri M., Altieri D.C. Endothelial cell activation by leukocyte microparticles. J Immunol 1998, 161:4382-4387.
71. Weiler H., Ruf W. Activated protein C in sepsis: the promise of non-anticoagulant activated protein C. Curr Opin Hematol 2008, 15:487-493. 10.1097/MOH.0b013e32830abdf4.
72. Lin S.M., Wang Y.M., Lin H.C., et al. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome and morality in patients with sepsis. Crit Care Med 2008, 36:683-689. 10.1097/CCM.0B013E31816537D8.
73. Mandel L.J. Primary active sodium transport, oxygen consumption, and ATP: coupling and regulation. Kidney Int 1986, 29:3-9.
74. Addabbo F., Montagnani M., Goligorsky M.S. Mitochondria and reactive oxygen species. Hypertension 2009, 53:885-892. 10.1161/HYPERTENSIONAHA.109.130054.
75. Harper M.E., Seifert E.L. Thyroid hormone effects on mitochondrial energetic. Thyroid 2008, 18:145-156. 10.1089/thy.2007.0250.
76. Psarra A.M., Sekeris C.E. Steroid and thyroid hormone receptors in mitochondria. IUBMB Life 2008, 60:210-223. 10.1002/iub.37.
77. Miller W.L. Steroidogenic enzymes. Endocr Dev 2008, 13:1-18. 10.1159/000134751.
78. Lill R., Hoffmann B., Molik S., Pierik A.J., Rietzschel N., Stehling O., et al. The role of mitochondria in cellular iron-sulfur protein biogenesis and iron metabolism. Biochim Biophys Acta 2012, 1823:1491-1508. 10.1016/j.bbamcr.2012.05.009.
79. Nourbakhsh N., Singh P. Role of renal oxygenation and mitochondrial function in the pathophysiology of acute kidney injury. Nephron Clin Pract 2014, 127(1-4):149-152. 10.1159/000363545.
80. Stidwill R.P., Rosser D.M., Singer M. Cardiorespiratory, tissue oxygen and hepatic NADH responses to graded hypoxia. Intensive Care Med 1998, 24:1209-1216.
81. Srinivasan S., Avadhani N.G. Cytochrome c oxidase dysfunction in oxidative stress. Free Radic Biol Med 2012, 53:1252-1263. 10.1016/j.freeradbiomed.2012.07.021.
82. Larsen F.J., Schiffer T.A., Weitzberg E., Lundberg J.O. Regulation of mitochondrial function and energetics by reactive nitrogen oxides. Free Radic Biol Med 2012, 53:1919-1928. 10.1016/j.freeradbiomed.2012.08.580.
83. Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev 2012, 92:791-896. 10.1152/physrev.00017.2011.
84. Bauer I., Pannen B.H. Bench-to-bedside review: carbon monoxide-from mitochondrial poisoning to therapeutic use. Crit Care 2009, 13:220. 10.1186/cc7887.
85. Szabó C., Módis K. Pathophysiological roles of peroxynitrite in circulatory shock. Shock 2010, 34(1):4-14. 10.1097/SHK.0b013e3181e7e9ba.
86. Bolaños J.P., Almeida A., Moncada S. Glycolysis: a bioenergetic or a survival pathway?. Trends Biochem Sci 2010, 35:145-149. 10.1016/j.tibs.2009.10.006.
87. Chung D.J., Szyszka B., Brown J.C., Hüner N.P., Staples J.F. Changes in the mitochondrial phosphoproteome during mammalian hibernation. Physiol Genomics 2013, 45(10):389-399. 10.1152/physiolgenomics.00171.2012.
88. Singer M., De Santis V., Vitale D., Jeffcoate W. Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet 2004, 364:545-548.
89. Reid V.L., Webster N.R. Role of microparticles in sepsis. Br J Anaesth 2012, 109(4):503-513. 10.1093/bja/aes321.
90. Souza A.C., Yuen P.S., Star R.A. Microparticles: markers and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and AKI. Kidney Int 2015, 87(6):1100-1108. 10.1038/ki.2015.26.
91. Piccin A., Murphy W.G., Smith O.P. Circulating microparticles: pathophysiology and clinical implications. Blood Rev 2007, 21:157-171.
92. Devaux P.F. Lipid transmembrane asymmetry and flip-flop in biological membranes and in lipid bilayers. Curr Opin Struct Biol 1993, 3:489-494.
93. Burnier L., Fontana P., Brenda R., Kwak B.R., Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009, 101:439-451.
94. Nieuwland R., Berckmans R.J., McGregor S., et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000, 95:930-935.
95. Ogura H., Kawasaka T., Tamaka H., Koh T., Tamaka R., Ozeki Y., et al. Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis. J Trauma 2001, 50:801-809.
96. Tans G., Rosing J., Thomassen M.C., Heeb M.J., Zwaal R.F., Griffin J.H. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991, 77:2641-2648.
97. Siljander P., Carpen O., Lassila R. Platelet-derived microparticles associate with fibrin during thrombosis. Blood 1996, 87:4651-4663.
98. Barry O.P., Kazanietz M.G., Pratico' D., FitzGerald G.A. Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C/mitogen-activated protein kinase-dependent pathway. J Biol Chem 1999, 274:7545-7556.
99. Puddu P., Puddu G.M., Cravero E., et al. The involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases. Can J Cardiol 2010, 26:140-145.
100. VanWijk M.J., VanBavel E., Sturk A., Nieuwland R. Microparticles in cardiovascular disease. Cardiovasc Res 2003, 59:277-287.
101. Holme P.A., Solum N.O., Brosstad F., Røger M., Abdelnoor M. Demonstration of platelet-derived microvesicles in blood from patients with activated coagulation and fibrinolysis using a filtration technique and western blotting. Thromb Haemost 1994, 72:666-671.
102. Horstman L.L., Jy W., Jimenez J.J., Ahn Y.S. Endothelial microparticles as markers of endothelial dysfunction. Front Biosci 2004, 9:1118-1135.
103. Mastronardi M.L., Mostefai H.A., Meziani F., et al. Circulating microparticles from septic shock patients exert differential tissue expression of enzymes related to inflammation and oxidative stress. Crit Care Med 2011, 39:1739-1748.
104. Pierrakos C., Vincent J.L. Sepsis biomarkers: a review. Crit Care 2010, 14:R15. 10.1186/cc8872.
105. Akerström B., Lögdberg L.E., Berggård I., Osmark P., Lindqvist A. Alpha(1)-Microglobulin: a yellow-brown lipocalin. Biochim Biophys Acta 2000, 1482:172-184.
106. Olsson M.G., Nilsson E.J., Rutardóttir S., Paczesny J., Pallon J., Akerström B. Bystander cell death and stress response is inhibited by the radical scavenger α(1)-microglobulin in irradiated cell cultures. Radiat Res 2010, 174:590-600. 10.1667/RR2213.1.
107. Olsson M.G., Allhorn M., Bülow L., Hansson S.R., Ley D., Olsson M.L., et al. Pathological conditions involving extracellular hemoglobin: molecular mechanisms, clinical significance, and novel therapeutic opportunities for α(1)-microglobulin. Antioxid Redox Signal 2012, 17:813-846. 10.1089/ars.2011.4282.
108. Akerström B., Maghzal G.J., Winterbourn C.C., Kettle A.J. The lipocalin alpha1-microglobulin has radical scavenging activity. J Biol Chem 2007, 282:31493-31503.
109. Gan S.L., Chia S.E., Chio L.F., Chan O.Y., Kwok S.F. Urinary beta 2- and alpha 1-microglobulin levels in normal subjects in Singapore. Occup Med 1994, 44:195-200.
110. Takagi K., Kin K., Itoh Y., Enomoto H., Kawai T. Human alpha 1-microglobulin levels in various body fluids. J Clin Pathol 1980, 33:786-791.
111. Weber M.H., Scholz P., Stibbe W., Scheler F. Alpha 1-microglobulin in the urine and serum in proteinuria and kidney insufficiency. Klin Wochenschr 1985, 63:711-717.
112. Yu H., Yanagisawa Y., Forbes M.A., Cooper E.H., Crockson R.A., MacLennan I.C. Alpha-1-microglobulin: an indicator protein for renal tubular function. J Clin Pathol 1983, 36:253-259.
113. Terzi I., Papaioannou V., Papanas N., Dragoumanis C., Petala A., Theodorou V., et al. Alpha1-microglobulin as an early biomarker of sepsis-associated acute kidney injury: a prospective cohort study. Hippokratia 2014, 18(3):262-268.
114. Shozushima T., Takahashi G., Matsumoto N., Kojika M., Okamura Y., Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 2011, 17:764-769. 10.1007/s10156-011-0254-x.
115. Endo S., Suzuki Y., Takahashi G., Shozushima T., Ishikura H., Murai A., et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother 2012, 18:891-897. 10.1007/s10156-012-0435-2.
116. Nakamura Y., Ishikura H., Nishida T., Kawano Y., Yuge R., Ichiki R., et al. Usefulness of presepsin in the diagnosis of sepsis in patients with or without acute kidney injury. BMC Anesthesiol 2014, 14:88. 10.1186/1471-2253-14-88.
117. Assicot M., Gendrel D., Carsin H., Raymond J., Guilbaud J., Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993, 341:515-518.
118. Cho S.Y., Choi J.H. Biomarkers of sepsis. Crit Rev Clin Lab Sci 2014, 46(1):1-12. 10.3947/ic.2014.46.1.1.
119. Herzum I., Renz H. Inflammatory markers in SIRS, sepsis and septic shock. Curr Med Chem 2008, 15:581-587.
120. Christ-Crain M., Muller B. Procalcitonin in bacterial infections e hype, hope, more or less?. Swiss Med Wkly 2005, 135:451-460.
121. Amour J., Birenbaum A., Langeron O., Le Manach Y., Bertrand M., Coriat P., et al. Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis of postoperative infection after vascular surgery. Crit Care Med 2008, 36:1147-1154. 10.1097/CCM.0b013e3181692966.
122. Nakamura Y., Murai A., Mizunuma M., Ohta D., Kawano Y., Matsumoto N., et al. Potential use of procalcitonin as biomarker for bacterial sepsis in patients with or without acute kidney injury. J Infect Chemother 2015, 21(4):257-263. 10.1016/j.jiac.2014.12.001.
123. Haase M., Bellomo R., Devarajan P., Schlattmann P., Haase-Fielitz A. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009, 54:1012-1024. 10.1053/j.ajkd.2009.07.020.
124. Cai L., Rubin J., Han W., Venge P., Xu S. The origin of multiple molecular forms in urine of HNL/NGAL. Clin J Am Soc Nephrol 2010, 5:2229-2235. 10.2215/CJN.00980110.
125. Glassford N.J., Schneider A.G., Xu S., Eastwood G.M., Young H., Peck L., et al. The nature and discriminatory value of urinary neutrophil gelatinase-associated lipocalin in critically ill patients at risk of acute kidney injury. Intensive Care Med 2013, 39:1714-1724. 10.1007/s00134-013-3040-7.
126. Martensson J., Xu S., Bell M., Martling C.R., Venge P. Immunoassays distinguishing between HNL/NGAL released in urine from kidney epithelial cells and neutrophils. Clin Chim Acta 2012, 413:1661-1667. 10.1016/j.cca.2012.05.010.
127. Doi K., Katagiri D., Negishi K., Hasegawa S., Hamasaki Y., Fujita T., et al. "Mild elevation of urinary biomarkers in prerenal acute kidney injury. Kidney Int 2012, 82:1114-1120. 10.1038/ki.2012.266.
128. Nejat M., Pickering J.W., Devarajan P., Bonventre J.V., Edelstein C.L., WalkerJ R.J., et al. Some biomarkers of acute kidney injury are increased in pre-renal acute injury. Kidney Int 2012, 81:1254-1262. 10.1038/ki.2012.23.
129. Haase M., Kellum J.A., Ronco C. Subclinical AKI-an emerging syndrome with important consequences. Nat Rev Nephrol 2012, 8:735-739. 10.1038/nrneph.2012.197.
130. Ronco C., Kellum J.A., Haase M. Subclinical AKI is still AKI. Crit Care 2012, 16:1-4. 10.1186/cc11240.
131. Giasson J., Li G.H., Chen Y. Neutrophil gelatinase-associated lipocalin (NGAL) as a new biomarker for non-acute kidney injury (AKI) diseases. Inflamm Allergy Drug Targets 2011, 10:272-282.
132. Axelsson L., Bergenfeldt M., Ohlsson K. Studies of the release and turnover of a human neutrophil lipocalin. Scand J Clin Lab Invest 1995, 55:577-588.
133. Mori K., Lee H.T., Rapoport D., Drexler I.R., Foster K., Yang J., et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005, 115:610-621.
134. Schmidt-Ott K.M., Mori K., Li J.Y., Kalandadze A., Cohen D.J., Devarajan P., et al. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2007, 18:407-413.
135. Vanmassenhove J., Glorieux G., Lameire N., Hoste E., Dhondt A., Vanholder R., et al. Influence of severity of illness on neutrophil gelatinase-associated lipocalin performance as a marker of acute kidney injury: a prospective cohort study of patients with sepsis. BMC Nephrol 2015, 16:18. 10.1186/s12882-015-0003-y.
136. Su L., Xie L., Liu D. Urine sTREM-1 may be a valuable biomarker in diagnosis and prognosis of sepsis-associated acute kidney injury. Crit Care 2015, 19(1):281. 10.1186/s13054-015-0998-2.
137. Lemarie J., Barraud D., Gibot S. Host response biomarkers in sepsis: overview on sTREM-1 detection. Methods Mol Biol 2015, 1237:225-239. 10.1007/978-1-4939-1776-1_17.
138. Zhang J., She D., Feng D., Jia Y., Xie L. Dynamic changes of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) reflect sepsis severity and can predict prognosis: a prospective study. BMC Infect Dis 2011, 11:53. 10.1186/1471-2334-11-53.
139. Su L., Feng L., Song Q., Kang H., Zhang X., Liang Z., et al. Diagnostic value of dynamics serum sCD163, sTREM-1, PCT, and CRP in differentiating sepsis, severity assessment, and prognostic prediction. Mediat Inflamm 2013, 2013:969875. 10.1155/2013/969875.
140. Derive M., Gibot S. Urine sTREM-1 assessment in diagnosing sepsis and sepsis-related acute kidney injury. Crit Care 2011, 15:1013. 10.1186/cc10533.
141. Powell T.C., Powell S.L., Allen B.K., Griffin R.L., Warnock D.G., Wang H.E. Association of inflammatory and endothelial cell activation biomarkers with acute kidney injury after sepsis. SpringerPlus 2014, 3:207. 10.1186/2193-1801-3-207.
142. Okusa M.D., Jaber B.L., Doran P., Duranteau J., Yang L., Murray P.T., et al. Physiological biomarkers of acute kidney injury: a conceptual approach to improving outcomes. Contrib Nephrol 2013, 182:65-81. 10.1159/000349967.
143. Cheng T.H., Ko F.C., Chang J.L., Wu K.A. Bronchiolitis obliterans organizing pneumonia due to titanium nanoparticles in paint. Ann Thorac Surg 2012, 93(2):666-669. 10.1016/j.athoracsur.2011.07.062.
144. Aydogdu M., Gursel G., Sancak B., Yeni S., Sari G., Tasyurek S., et al. The use of plasma and urine neutrophil gelatinase associated lipocalin (NGAL) and cystatin C in early diagnosis of septic acute kidney injury in critically ill patients. Dis Markers 2013, 34:237-246. 10.3233/DMA-130966.
145. Giamarellos-Bourboulis E.J., Dimopoulou I., Kotanidou A., Livaditi O., Pelekanou A., Tsagarakis S., et al. Ex-vivo effect of dexamethasone on cytokine production from whole blood of septic patients: correlation with disease severity. Cytokine 2010, 49:89-94. 10.1016/j.cyto.2009.08.016.
146. Page M.K., Bukki J., Luppa P., Neumeier D. Clinical value of cystatin C determination. Clin Chim Acta 2000, 297:67-72.
147. Candido S., Maestro R., Polesel J., Catania A., Maira F., Signorelli S.S., et al. Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget 2014, 5:1576-1594.